Portal de Periódicos da CAPES

Non–Small Cell Lung Cancer Treated with Erlotinib: Heterogeneity of 18 F-FDG Uptake at PET—Association with Treatment Response and Prognosis

2015; Radiological Society of North America; Volume: 276; Issue: 3 Linguagem: Inglês

10.1148/radiol.2015141309

1527-1315

Gary Cook, Mary O’Brien, Muhammad Siddique, Sugama Chicklore, Hoi Yin Loi, Bhupinder Sharma, R. Punwani, Paul Bassett, Vicky Goh, Sue Chua,

Lung Cancer Diagnosis and Treatment

To determine if first-order and high-order textural features on fluorine 18 ((18)F) fluorodeoxyglucose (FDG) positron emission tomography (PET) images of non-small cell lung cancer (NSCLC) (a) at baseline, (b) at 6 weeks, or (c) the percentage change between baseline and 6 weeks can predict response or survival in patients treated with erlotinib.